FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2829-2831 June 26, 2008 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Brooke, B. S. PubMed Citation

Almost three decades ago, Victor McKusick and I reviewed Marfan's syndrome in the Journal and advised traditional medical and surgical approaches to management.¹ The holy grail at that time was the cause of this autosomal dominant condition, based on the common presumption that understanding the cause would lead directly to effective therapy. In fact, life expectancy improved dramatically in subsequent years for all but the most severely affected patients, despite a lack of understanding of the underlying connective-tissue defect.² Dissection of the aorta was and remains the most common cause of death. However, the evolution of ever more effective surgical . . . [Full Text of this Article]

Source Information

From the Center for the Integration of Genetic Healthcare Technologies, Departments of Medicine and Genetics, University of Pennsylvania School of Medicine, Philadelphia.

This article has been cited by other articles:

• Pyeritz, R. E (2009). Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart 95: 173-175 [Full Text]